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Tumors
The use of chemotherapy in low-grade gliomas has been very thoroughly studied in the setting 
of oligodendrogliomas and oligoastrocytomas. According to the Radiation Oncology staff here 
at  Thomas Jefferson University Hospital, the current practices in our institution are as follows: 
Three-dimensional conformal radiation is provided in patients with low-grade gliomas 2-4 weeks 
post-operatively. The total dose ranges between 50 and 54 Gy and is delivered in 1.8 fractions 
at five fractions per week. In the presence of recurrence, a stereotactic boost with or without 
re-operation is provided. For the most part, these practices are similar to the aforementioned 
recommendations. However, factors such as the age of the patient, and optimal timing of the 
radiation are not considered in our institution at this given time. 
Chemotherapy is restricted to patients with known pathology of oligodendroglioma. PCV is the 
chemotherapeutic agent of choice in both research recommendations and our clinical practice. 
Specifically, the use of PCV in an established oligodendroglioma case has shown to increase the time 
to progression and provide a statistically significant survival benefit. Furthermore, this response is 
augmented in patients with chromosomal analysis positive for the 1p and 19q allele mutation. For 
these patients, further chromosomal analysis is performed in order to predict the chemotherapy 
response rate. Recurrent disease is managed on a patient specific basis.  
There is no level I evidence on the use of chemotherapy in the remaining categories of low-grade 
gliomas. A single randomized prospective trial by the South West Oncology Group studied the effect 
of post-operative radiation with and without lomustine (CCNU) in low-grade gliomas; although 
the median survival time of patients were 4.5 and 7.4 years respectively, the results did not reach 
statistical significance and the study closed early due to slow patient accrual. The increasing use of 
Temazolamide in malignant gliomas and its minimal cumulative toxicity have triggered additional 
research in its use in low-grade gliomas.
An extensive medical literature search was performed on the topic of adjuvant treatment in the 
management of low-grade gliomas. Although no specific guidelines were found, several papers 
were reviewed that included recommendations for clinical practice. The two sets of guidelines that 
were investigated were the use of adjuvant chemotherapy and radiation in low-grade gliomas. The 
following five references were reviewed:
1. Lang FF, Gilbert MR: Diffusely Infiltrative Low-Grade Gliomas in Adults.  J Clin Neuro 2006; 24 
(8): 1236-1245. 
2. Frappaz D, Chinot O, et al: Summary Version of the Standards, Options and Recommendations 
for the Management of Adult Patients with Intracranial Glioma. British J of Cancer 2003; 89 
(Supp I): 73-83.
3. Lesser G: Chemotherapy of Low-Grade Gliomas. Sem Rad Onc 2001; 11 (2): 138-144. 
4. Dropohe E: Low-Grade Gliomas in Adults. Curr Treatm Options Neuro 2004; 6: 265-271.
5. Mason WP: Advances in the Management of Low-Grade Gliomas. Can J Neuro Sciences 2005; 
32: 18-26.
A thorough review of these research articles has shown that although there are no specific 
standards (guidelines) for the adjuvant treatment of low-grade gliomas, there are multiple options 
and recommendations. Specifically, in the use of radiation therapy, the recommended dose is low 
(between 50 and 55 Gy in daily fractions between 1.8 and 2.0 Gy at five fractions per week). This 
optimal dose was reached from Class I evidence of least toxicity with equal survival benefit (EORTC 
study 2284).  The timing of radiotherapy was also studied and Class I data from the second EORTC 
study showed that early post-operative radiotherapy prolonged the time to tumor progression at 
a five-year estimate from 37% (in observation 
control group) to 44%. However, the benefit in 
overall survival of the patients did not reach 
statistical significance. Being that radiation 
toxicity in this setting has not been adequately 
studied, mixed options were found proposing 
immediate post-operative radiation versus 
radiation at the time of progression only. A 
useful recommendation was to use radiation in 
patients greater than 40 years of age only; this 
protects the younger patient from radiation 
toxicity, being that the natural progression of 
the disease has a more favorable outcome in 
this age bracket. The fundamental question 
of whether radiation should be given in 
patients with low-grade-gliomas was not 
addressed in most of these studies. Most 
studies provided with Class II evidence (at 
best) with retrospective studies showing a five-
year survival benefit from 10% (with surgery 
alone) to 32% (with surgery and radiation). 
However, most of these series have many flaws 
and no options or recommendations could be 
extracted from them. Most of these studies 
investigated the incidence and treatment 
of these tumors in the adult population. 
The guidelines are different in the pediatric 
population were the incidence of low-grade 
gliomas is much higher, and radiation options 
extremely limited secondary to the harmful 
effects of radiation in the developing brain.
Similarly to radiation, all these recommenda-
tions were made for the adult population, 
which is the main target population in our 
institution. Chemotherapeutic agents, regi-
mens, and overall therapy are different in the 
pediatric population.
This document describes a clinical guideline 
for the treatment of patients with low-grade 
gliomas with radiation and chemotherapy 
following surgical resection. The patient 
population targeted is adults ranging from 
18 to 70 years of age. All patients will be 
post-operative from lesion resection the final 
pathology of which should be consistent with 
low-grade glioma.
Overall, radiation therapy should not be 
delivered routinely following initial resection. 
Based on the review paper by WP Mason, 
Stavropoula I. Tjoumakaris, MD
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radiation therapy benefits counteract the 
deleterious effects on the brain in patients with 
recurrent low-grade gliomas only.  Therefore, 
radiation therapy should be delivered in 
patients who present with either clinical or 
radiographic recurrence.   
Based on level I clinical evidence provided 
in the Summary Guidelines published in the 
British Journal of Cancer, the total radiation 
dose should be between 50 and 54 Gy divided 
in 1.8 Gy fractions delivered at five fractions 
per week.   In the setting of the initial post-
operative period, an exception is made in older 
patients (greater than 40 years of age), with two 
or more of the following negative prognostic 
indicators: contrast enhancement, post-
operative residual of large size with continuing 
mass effect, rapidly increasing volume in 
follow-up imaging, uncontrolled epilepsy, and 
involvement of deeper or functional structures. 
Radiation therapy should be delivered in this 
setting according to the aforementioned 
dosing guidelines.
Chemotherapy should be delivered in all 
patients with post-operative pathology 
consistent with either oligodendroglioma or 
oligoastrocytoma. In addition, all these patients 
should undergo chromosomal analysis for the 
1p 19q allele mutation. The agent of choice is 
the PCV chemotherapeutic combination. In 
the remaining group of low-grade gliomas, 
post-operative chemotherapy should be 
administered in patients presenting with 
recurrence and who have had post-operative 
radiation either following the initial resection 
or the recurrence. The agent of choice is 
also PCV, although temazolamide should 
be used if recurrence is characterized by 
either contrast enhancement in radiographic 
imaging or a higher Ki-67 labeling index 
upon re-resection.   Sophisticated analysis of 
the RTOG 98-02 results will further refine or 
change the aforementioned guidelines.
These guidelines should be reviewed overall 
and in an individual patient basis by an 
organized oncological clinical team comprised 
of neurosurgeons, radiation oncologists, and 
medical oncologists. Careful adjustments 
should be made on a patient-specific basis and 
overall, as further research and data accrue 
over the years.  Careful implementation could 
be achieved starting at the Medical Records 
office.  Patients with a post-operative diagnosis 
of low-grade gliomas should be given a specific 
code or tag so that if they have not been 
assigned to an integrated oncological team as 
an inpatient, during their post-operative office 
visit, they could be referred to an oncologist 
(radiation and medical) at the registration 
desk.   Due to the economical restrictions of 
such referrals, triage nurses, guided by the 
neurosurgeon’s recommendations, could 
decide based on these guidelines whether one, 
both, or neither referrals should be made.  The 
oncological team should keep frequent 
correspondence on the patient clinical status 
and meet at scheduled intervals to discuss the 
treatment plan and adjustments thereof.
Future guidelines on adjuvant chemotherapy 
will be refined from the results of the RTOG 
study, which investigates the outcome of 
high-risk patients with low-grade gliomas 
in the setting of radiation with and without 
chemotherapy (PCV). This trial closed in 2002 
and the results are still maturing.  The suggested 
clinical guidelines provide a strong foundation 
upon which additional research and clinical 
testing will further refine standard of treatment.
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